Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Researchers survey Weight-Loss drug users to understand Real-World experiences

NCT ID NCT07154238

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects information through online surveys from about 2,500 adults in Australia, Germany, UAE, and Spain who have been prescribed injectable semaglutide for weight management. The goal is to understand their characteristics, treatment experiences, and changes in weight and quality of life. No new treatment or lab tests are involved; it is purely a research survey.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,546 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will collect quantitative and qualitative data from individuals treated with injectable semaglutide for weight management in real-world settings. The study will include two groups of participants: 1. Individuals who belong to or are recruited to an opt-in panel in the countries of interest and who have initiated injectable semaglutide for weight management. They will be classified according to the time when they first initiated treatment with injectable semaglutide for weight management. 2. HCPs who prescribe injectable semaglutide for weight management will be recruited from an existing opt-in panel in the countries of interest.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes". 1. Electronically provided consent obtained before any study-related activities can be completed. 2. Age above or equal to 18 years at the time of providing informed consent. 3. Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain. 4. Have been prescribed and initiated injectable semaglutide for weight management prior to study screening. * For an eligible participant (HCPs), all inclusion criteria must be answered "yes". 1. Electronically provided consent obtained before any study-related activities can be completed. 2. Practice in a participating country: Australia, Germany, UAE, and Spain. 3. See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month. 4. Treat at least 10 adult patients per month for weight management. 5. Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs). 6. Prescribe injectable semaglutide for weight management. 7. Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others. Exclusion Criteria: * For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no". 1. Unwillingness or language barriers precluding adequate understanding or cooperation. 2. Is currently or planning to become pregnant in next six months. 3. Is taking injectable semaglutide for Type 2 diabetes management only. * For an eligible participant (HCPs), all exclusion criteria must be answered "no". 1. Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview. 2. Unwillingness or language barriers precluding adequate understanding or cooperation. 3. Only treats patients under 18 years of age.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Novo Nordisk Investigational Site

    Bad Oeynhausen, 32545, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.